Home/Filings/4/0001171000-17-000051
4//SEC Filing

Nexvet Biopharma plc 4

Accession 0001171000-17-000051

CIK 0001618561operating

Filed

Jul 4, 8:00 PM ET

Accepted

Jul 5, 1:30 PM ET

Size

19.0 KB

Accession

0001171000-17-000051

Insider Transaction Report

Form 4
Period: 2017-07-01
Farrell Geraldine T
VP Operations, General Counsel
Transactions
  • Exercise/Conversion

    Option to Purchase Shares

    2017-07-012,8660 total(indirect: By Geraldine Therese Farrell & Andrew John Benston <Bulla Bulla Family A/C>)
    Exercise: $0.13From: 2017-07-01Exp: 2019-07-01Ordinary Shares (2,866 underlying)
  • Exercise/Conversion

    Ordinary Shares

    2017-07-01$0.13/sh+10,000$1,25016,640 total
  • Exercise/Conversion

    Ordinary Shares

    2017-07-01$0.13/sh+2,340$29318,980 total
  • Exercise/Conversion

    Ordinary Shares

    2017-07-01$0.13/sh+6,194$77433,180 total(indirect: Geraldine Therese Farrell & Andrew John Benston <Bulla Bulla Family A/C>)
  • Exercise/Conversion

    Restricted Share Units

    2017-07-0110,00030,000 total
    Exercise: $0.13From: 2017-07-01Exp: 2021-07-01Ordinary Shares (10,000 underlying)
  • Exercise/Conversion

    Ordinary Shares

    2017-07-01$0.13/sh+2,866$35826,986 total(indirect: By Geraldine Therese Farrell & Andrew John Benston <Bulla Bulla Family A/C>)
  • Exercise/Conversion

    Restricted Share Units

    2017-07-012,3404,678 total
    Exercise: $0.13From: 2017-07-01Exp: 2020-07-01Ordinary Shares (2,340 underlying)
  • Exercise/Conversion

    Option to Purchase Shares

    2017-07-016,1940 total(indirect: Geraldine Therese Farrell & Andrew John Benston <Bulla Bulla Family A/C>)
    Exercise: $0.13From: 2016-11-05Exp: 2023-11-05Ordinary Shares (6,194 underlying)
Footnotes (3)
  • [F1]The reporting person and her spouse have shared voting and dispositive power with respect to these reported securities.
  • [F2]10,000 of the Restricted Share Units vested and became convertible on 7/1/17 and 10,000 of the Restricted Share Units shall vest and become convertible on each of 7/1/18, 7/1/19 and 7/1/20, in each case subject to payment of the nominal value per share to Issuer within 30 days of vesting.
  • [F3]2,340 of the Restricted Share Units vested and became convertible on 7/1/17 and 2,339 of the Restricted Share Units shall vest and become convertible on each of 7/1/18 and 7/1/19, in each case subject to payment of the nominal value per share to Issuer within 30 days of vesting.

Issuer

Nexvet Biopharma plc

CIK 0001618561

Entity typeoperating
IncorporatedIreland

Related Parties

1
  • filerCIK 0001618561

Filing Metadata

Form type
4
Filed
Jul 4, 8:00 PM ET
Accepted
Jul 5, 1:30 PM ET
Size
19.0 KB